01 June 2005 : Original article
Pharmaceutical availability of gliclazide from selected matrix formulation tablets
Tadeusz W. Hermann, Roman Dobrucki, Stefan Piechocki, Matylda Resztak, Robert RehMed Sci Monit 2005; 11(6): BR181-188 :: ID: 16492
Abstract
Summary
Background: Immediate release and modifi ed release gliclazide formulation tablets are available on the market. We decided to measure the kinetics of gliclazide release from these tablets, and to propose our own technique for producing gliclazide matrix tablets, comparing their release kinetic profi le with the gliclazide tablets available on the market.
Material/Methods: A BP 2001 dissolution test was performed for selected gliclazide formulation tablets, and the water solubility of authentic gliclazide samples from different manufacturers was determined by UV spectrometry.
Results: Diabezidum (Jelfa) and diabrezide (Molteni) tablets are classic gliclazide oral formulations, releasing the drug very rapidly in vivo and in vitro according to BP 2001 (approximately 99% at 100 min). However, diaprel tablets (Servier) are modifi ed release formulations (67% released in in vitro conditions at 8 h). The matrix tablets (C) produced according to our own formula demonstrated a release profi le similar to diaprel tablets. The MDT, calculated in order to classify the tablets we studied, ranged from 4.6 to 76.4 minutes for immediate release (IR) tablets (diabrezide, diabezidum, I and F), and from 279.6 to 701.2 minutes for sustained-release (SR) tablets (E, G, C, diaprel, J, B,
D, H, K, A).
Conclusions: The dissolution process of immediate release gliclazide formulation tablets (diabrezide, diabezidum, F, I) obeys a fi rst-order equation. However, the process for modifi ed release formulation tablets (diaprel, diaprel MR, A, B, C, D G, H, J, K) proceeds according to a zero-order equation
Keywords: Gliclazide - chemistry, Gliclazide - pharmacokinetics, Administration, Oral, Calibration, Gliclazide - pharmacokinetics, Hydrogen-Ion Concentration, Hypoglycemic Agents - pharmacokinetics, Solubility, Spectrophotometry, Ultraviolet, Tablets
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
15 Apr 2024 : Laboratory Research
The Role of Copper-Induced M2 Macrophage Polarization in Protecting Cartilage Matrix in OsteoarthritisMed Sci Monit In Press; DOI: 10.12659/MSM.943738
07 Mar 2024 : Clinical Research
Knowledge of and Attitudes Toward Clinical Trials: A Questionnaire-Based Study of 179 Male Third- and Fourt...Med Sci Monit In Press; DOI: 10.12659/MSM.943468
08 Mar 2024 : Animal Research
Modification of Experimental Model of Necrotizing Enterocolitis (NEC) in Rat Pups by Single Exposure to Hyp...Med Sci Monit In Press; DOI: 10.12659/MSM.943443
18 Apr 2024 : Clinical Research
Comparative Analysis of Open and Closed Sphincterotomy for the Treatment of Chronic Anal Fissure: Safety an...Med Sci Monit In Press; DOI: 10.12659/MSM.944127
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952